Medical News Today: Everything you need to know about methylphenidate
Methylphenidate is a stimulant drug that doctors prescribe to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. Learn about how it works, its side effects, and typical dosages here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 12, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news
Medical News Today: Everything you need to know about Adderall
In this article, learn all about Adderall, a type of stimulant medication that doctors sometimes prescribe to treat ADHD or narcolepsy. We cover the uses, side effects, dosage, and more. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 3, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news
Medical News Today: Is hair loss a side effect of Adderall?
Adderall is a combination drug for the short-term treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. Although it is generally a safe and effective drug, it can cause a range of side effects. Alopecia, or hair loss, is a potential but uncommon side effect of taking Adderall. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 5, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news
The risk of hospitalization for motor vehicle accident injury in narcolepsy and the benefits of stimulant use: a nationwide cohort study in Taiwan - Tzeng NS, Hsing SC, Chung CH, Chang HA, Kao YC, Mao WC, Yang CCH, Kuo TBJ, Chen TY, Chien WC.
STUDY OBJECTIVES: To examine the risk of hospitalization for motor vehicle accident injury (MVAI) in patients with narcolepsy and the effects of stimulant use on MVAI occurrence in patients with narcolepsy. METHODS: This is a population-based, retr... (Source: SafetyLit)
Source: SafetyLit - June 4, 2019 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Medical News Today: What are the side effects and risks of Ritalin?
Ritalin (methylphenidate) is a stimulant medication for the treatment of ADHD and narcolepsy. Ritalin can cause side effects and has the potential for misuse and addiction. Researchers are investigating the long-term safety and effectiveness of this drug in children and adolescents. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 31, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news
Personal trainer, 24, falls asleep up to 16 TIMES a day because of her narcolepsy
Belle Hutt, from Oxford, was terrified of her sudden sleep attacks because her condition also caused sleep paralysis and hallucinations. She now controls her sleeping with an exercise routine. (Source: the Mail online | Health)
Source: the Mail online | Health - May 29, 2019 Category: Consumer Health News Source Type: news
FDA Clears Solriamfetol (Sunosi) for Narcolepsy, OSA FDA Clears Solriamfetol (Sunosi) for Narcolepsy, OSA
The dual-acting dopamine and norepinephrine reuptake inhibitor showed durable effects in reducing excessive sleepiness in patients with narcolepsy or obstructive sleep apnea.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 21, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
FDA approves Jazz Pharmaceutical sleep disorder drug
The Food and Drug Administration approved Jazz Pharmaceutical's new drug application for Sunosi, a once-daily medicine designed to improve wakefulness in adult patients suffering from narcolepsy and obstructive sleep apnea.
Sunosi is expected to be commercially available in the United States following the final scheduling decision by the U.S. Drug Enforcement Administration, which is typically rendered within 90 days of FDA approval.
Jazz Pharmaceuticals, which is based in Dublin, Ireland,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 21, 2019 Category: Biotechnology Authors: John George Source Type: news
FDA approves Jazz Pharmaceutical sleep disorder drug
The Food and Drug Administration approved Jazz Pharmaceutical's new drug application for Sunosi, a once-daily medicine designed to improve wakefulness in adult patients suffering from narcolepsy and obstructive sleep apnea.
Sunosi is expected to be commercially available in the United States following the final scheduling decision by the U.S. Drug Enforcement Administration, which is typically rendered within 90 days of FDA approval.
Jazz Pharmaceuticals, which is based in Dublin, Ireland,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 21, 2019 Category: American Health Authors: John George Source Type: news
FDA Approves Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
DUBLIN, March 20, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration (FDA) approved Sunosi (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 20, 2019 Category: Drugs & Pharmacology Source Type: news
Medical News Today: Why narcolepsy is an autoimmune condition
New research finds an autoreactive type of immune cell related to narcolepsy, adding to the mounting body of evidence that the condition is autoimmune. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 20, 2019 Category: Consumer Health News Tags: Sleep / Sleep Disorders / Insomnia Source Type: news
FDA decision on Jazz Pharmaceuticals narcolepsy drug expected Wednesday
The Food and Drug Administration is expected to make a decision by Wednesday on a new drug application filed by Jazz Pharmaceuticals for its experimental narcolepsy drug solriamfetol.
The FDA was originally set to make a ruling on the application in late December, but its review was extended by three months after the federal agency determined an submission made by Jazz during discussions regarding draft labeling for solriamfetol constituted a "major amendment" to its applicatio n. That resulted in… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 19, 2019 Category: Pharmaceuticals Authors: John George Source Type: news
New proof that narcolepsy is an autoimmune disease
(University of Copenhagen The Faculty of Health and Medical Sciences) Researchers from the University of Copenhagen have discovered autoreactive cells in persons suffering from narcolepsy. This is a new, important proof that the sleep disorder is an autoimmune disease. This knowledge may lead to better treatment of the chronic condition, the researchers behind the new discovery believe. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 15, 2019 Category: Biology Source Type: news
Lannett stock up 6 percent following ADHD drug distribution deal
Lannett Co. Inc. entered into an agreement with Elite Pharmaceuticals and SunGen Pharma to be the exclusive U.S. distributor of a generic version of Adderall, a medicine prescribed to treat attention-deficit hyperactivity disorder and narcolepsy.
Tim Crew, CEO of Lannett (NYSE: LCI), said the Northeast Philadelphia company plans to launch the generic version of Adderall in the "near term." He added Lannett is hopeful it can expand its relationship with Elite of Northvale, N.J., and SunGen of Princeton,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 11, 2019 Category: Biotechnology Authors: John George Source Type: news
Assessing readiness to drive in adolescents with narcolepsy: what are providers doing? - Ingram DG, Marciarille AM, Ehsan Z, Perry GV, Schneider T, Al-Shawwa B.
PURPOSE: There are no universally accepted guidelines for assessing driving readiness in adolescents with narcolepsy. The purpose of the present study was to survey pediatric sleep medicine providers regarding their current practice patterns for assessing ... (Source: SafetyLit)
Source: SafetyLit - February 11, 2019 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
